Israel finds probable link between Pfizer Covid shot and heart inflammation

According to a study, there were 275 cases of myocarditis identified between December 2020, when the vaccination drive began, and May 2021, including 148 cases within a month after vaccination.

Israel health officials have found a probable link between Pfizer Inc. and BioNTech SE’s coronavirus vaccine and dozens of cases of heart inflammation in young men following the second dose of the vaccine, the Health Ministry said late Tuesday.

The vaccine has been administered to more than 5 million people in the country. The Health Ministry is currently discussing whether to expand the inoculation drive to 12-15 year olds, after the U.S. Food and Drug Administration authorized its use for the age group.

According to a study by health officials, there were 275 cases of myocarditis identified between December 2020, when the vaccination drive began, and May 2021, including 148 cases within a month after vaccination. Of these, 27 cases occurred after the first dose and 121 following the second dose. In both cases, about half were in people with previous medical conditions.

At this time, there’s still no indication that the cases are due to the vaccine, Pfizer said in a statement. Myocarditis is often caused by viral infections, and Covid infections have been reported to cause the condition, the U.S. drugmaker said. BioNTech said more than 300 million doses of the Covid-19 vaccine have been administered globally and the “benefit risk profile” of the vaccine remains positive.

“A careful assessment of the reports is ongoing and it has not been concluded,” the company said. “Adverse events, including myocarditis and pericarditis, are being regularly and thoroughly reviewed by the companies as well as by regulatory authorities.”

Most of the cases occurred in young men, especially those between 16 and 19 years old. In most cases, patients were hospitalized for four days or less, and in 95% of the cases were classified as mild, the ministry said.

Israel said in late April that it was looking into the cases to see if there’s a connection with the vaccine.

Moderna may go for mix of vaccine doses
 
Moderna is gearing up to halve the dose of its Covid-19 vaccine, the US drugmaker said, so that it can also be used to combat variants and inoculate children. “We're assuming that as of 2022, we are going to have a mix of dose levels on the market,” a spokeswoman said.
 
It has agreed a deal with Swiss-based drugmaker Lonza which said a new drug substance production line in Geleen, Netherlands, will have capacity to make ingredients for up to 300 million doses annually at 50 micrograms per dose.
 
Russia’s CoviVac ‘80% effective’
 
Russia's third vaccine against Covid-19, CoviVac, is more than 80 pe cent effective according to preliminary data, the Interfax news agency cited the vaccine's developer as saying. The Chumakov Centre could produce six times more than the previously planned 10 million doses of the vaccine a year, Interfax added.